A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

BACKGROUND: Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clinical practice, including elderly patients, and tho...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Hai-Yan, Feng, Jifeng, Shi, Meiqi, Zhao, Jun, Wang, Yuyan, Chang, Jianhua, Wang, Jialei, Cheng, Ying, Zhu, Jing, Tan, Eng-Huat, Li, Kai, Zhang, Yiping, Lee, Victor, Yang, Cheng-Ta, Su, Wu-Chou, Lam, David Chi-Leung, Srinivasa, B. J., Rajappa, Senthil, Ho, Ching-Liang, Lam, Kwok Chi, Hu, Yi, Bondarde, Shailesh Arjun, Liu, Xiaoqing, Tian, Yahui, Xue, Zhiyi, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Zhou, Caicun, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783858/
https://www.ncbi.nlm.nih.gov/pubmed/35020119
http://dx.doi.org/10.1007/s11523-021-00859-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783858/
https://www.ncbi.nlm.nih.gov/pubmed/35020119
http://dx.doi.org/10.1007/s11523-021-00859-6

Ejemplares similares